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3Department of Medicine I, JW Goethe University Hospital, Frankfurt, GermanyRibavirin in combination with peginterferon alfa shows strong clinical eﬃcacy against chronic hepatitis C, and is now
established as the standard of care. However, the precise role of ribavirin is still being deﬁned, suggesting that optimal
ribavirin dose should be maintained over the whole treatment period. Ribavirin dosage varies by bodyweight for genotype
1 disease (1000 mg/day in patients 675 kg and 1200 mg/day in patients >75 kg), whereas 800 mg/day is suﬃcient to ensure
optimal response in all genotype 2/3 patients. Similarly, genotype 1 patients beneﬁt from 48 weeks of therapy, while 24
weeks is suﬃcient for genotype 2/3 disease.
Recent data suggest treatment success is dependent on cumulative ribavirin exposure, as patients who receive <60% of
the planned dose have lower response rates, regardless of whether reductions are from temporary interruptions or prema-
ture cessation of therapy. All patients should be monitored for hemolytic anemia, as early diagnosis allows management
through small dose reductions and stepwise return to the target dose, maximizing cumulative exposure. Despite these
recent advances in our knowledge, many questions remain, such as whether the role of ribavirin will change or even be
eliminated as new therapies are developed.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Ribavirin has been studied for over 20 years as a
potential therapy against a number of RNA and DNA
viruses, including human immunodeﬁciency virus, respi-
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(HCV) [1]. Initial studies of ribavirin monotherapy
showed limited direct antiviral activity against chronic
HCV, with HCV RNA clearance seen in a small percent-
age (10%) of patients in one study [2] but no eﬀect on
viral levels in others [2–6], although improvement of
alanine aminotransferase levels was commonly described.
Pilot studies conducted around the same time showed
much more promising results, when twice-daily ribavirin
(1000/1200 mg/day) was added to interferon-alfa
therapy (3 MU thrice weekly), resulting in improved
end-of-treatment and end-of-follow-up responses [7].
Subsequent large clinical trials conﬁrmed this ﬁnding,
demonstrating signiﬁcant improvements in sustained
viral response (SVR; deﬁned as undetectable HCV
RNA 24 weeks after completion of therapy and reduced
levels of relapse following ribavirin combination therapy
[8–10].Published by Elsevier B.V. All rights reserved.
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[pegylated interferon alfa-2a and pegylated interferon
alfa-2b], with longer half-lives than the non-pegylated
form allow for weekly dosing. Studies combining ribavi-
rin with peginterferon alfa have consistently demon-
strated further improvements in end-of-treatment
response (ETR; deﬁned as undetectable HCV RNA at
end of therapy) and SVR, largely driven by a decrease
in the rate of relapse (Fig. 1) [11–13]. Once-weekly sub-
cutaneous peginterferon alfa plus twice-daily oral ribavi-
rin is now regarded as the standard of care for the
treatment of patients with chronic HCV infection.
It is clear that higher response rates are achieved in
the majority of patients who are able to tolerate/adhere
to ribavirin dosing, indicating the importance of cumu-
lative ribavirin exposure [14]. For this reason, optimiza-
tion of ribavirin dosing and duration of therapy,
accompanied by careful clinical management, is crucial
to ensure the best chance of a durable response to ther-
apy. This review will focus on the clinical importance of
ribavirin, in particular the selection and maintenance of
the optimal ribavirin dosing strategy, to achieving the
therapeutic goal of sustained viral suppression in
patients with chronic HCV.2. The impact of genotype on response to ribavirin plus
peginterferon alfa in HCV
Combination therapy with peginterferon alfa and
ribavirin has demonstrated high SVR rates and corre-
spondingly low rates of virologic relapse in large clinical
trials [11–13]. However, response to therapy varies
according to HCV genotype. Genotype 2/3 HCV is
more responsive to therapy than genotype 1 disease,
with comparatively higher SVR rates observed with
most therapeutic options studied to date [8,9]. DespiteFig. 1. Increased rates of SVR by prevention of relapse in patients with
chronic HCV after the addition of ribavirin to 48 weeks’ treatment with
pegylated interferon alfa [12].the good response to therapy in genotype 2/3 patients,
there is still a clear beneﬁt of adding ribavirin to therapy
with peginterferon alfa, and SVR rates of approximately
80% have been described with this combination [11–
13,15–18]. The impact of peginterferon plus ribavirin
on response in other HCV genotypes (4, 5 and 6) is less
well understood, as these genotypes are less common
and tend to be pooled for analysis or excluded from lar-
ger trials.
Although patients with genotype 1 disease are gener-
ally less responsive to therapy, a sustained response to
ribavirin plus peginterferon therapy is still seen in
approximately 50% of patients with genotype 1 [11–
13,19]. A large, randomized, controlled study, compar-
ing peginterferon alfa-2a alone (180 lg/week) with
peginterferon alfa-2a plus ribavirin (1000/1200 mg/
day) or interferon alfa-2b (3 MU thrice weekly) plus
ribavirin over 48 weeks clearly demonstrated that ribavi-
rin signiﬁcantly improves outcomes in genotype 1
patients [12]. In this study, SVR rates in genotype 1
patients were highest in the peginterferon alfa-2a plus
ribavirin arm (46%), compared with the interferon
alfa-2b plus ribavirin arm (36%; p = 0.01) or the pegin-
terferon alfa-2a alone arm (21%; p < 0.001). Other clin-
ically important endpoints such as rate of relapse and
ETR are also favorable when ribavirin is included as
part of standard therapy [11,12].3. Mechanism of action, pharmacokinetics and viral
kinetics
A range of mechanisms have been proposed, any or
all of which may contribute to the strong antiviral eﬀect
observed in clinical practice. Ribavirin is a guanosine
analog, which is rapidly absorbed and distributed fol-
lowing oral administration with maximum plasma con-
centrations reached within approximately 1.5 h. Due
to extensive distribution to non-plasma compartments,
the apparent volume of distribution is greater than
2000 L. Following multiple dosing, steady state is
achieved in approximately 4 weeks with a terminal
half-life of approximately 12 days [20]. The main route
of elimination is via the kidneys, and it has been sug-
gested that the optimal dosing strategy may be based
on renal function, as measured by creatinine clearance,
rather than bodyweight, as used currently [21]. Ribavi-
rin alone has a relatively minor antiviral eﬀect in
HCV-infected patients, but in combination with pegin-
terferon alfa it appears to enhance the second and third
phases of viral decay, thereby reducing the chance of
relapse, particularly in patients with low responses to
the interferon component of therapy [22–24].
The proposed mechanisms of ribavirin antiviral activ-
ity have been reviewed elsewhere [25–27], and suggested
mechanisms include error catastrophe resulting from
Fig. 2. SVR rates in patients with genotype 1 chronic HCV in pivotal
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RNA during replication [28,29], direct inhibition of
HCV RNA replication [30,31], inosine-monophospate-
dehydrogenase (IMPDH) inhibition [32], and immuno-
modulation [33,34]. Most attention has been given to
the theory that ribavirin acts as a mutagen, and a num-
ber of studies have described a signiﬁcant but in some
cases transient increase in mutation rate with ribavirin
monotherapy both in vitro and in vivo [35–37].
However, it is important to note that, while much of
the evidence regarding the mode of action of ribavirin is
derived from studies of ribavirin monotherapy, strong
antiviral activity is only seen when used as combination
therapy; indeed synergism between ribavirin and inter-
feron alfa has been demonstrated in vitro [38,39],
although the mechanism of action driving this synergism
has yet to be deﬁned.
Of note, the mutagenic eﬀect of ribavirin appears to
be abolished in vivo when administered in combination
with peginterferon alfa, although this may be due to
the activity of peginterferon alfa masking a mutagenic
eﬀect [36]. Although debate is ongoing as to which of
these modalities are responsible for the antiviral eﬀect
of ribavirin in combination with peginterferon alfa, it
is clear that ribavirin activity is dose/exposure depen-
dent [14,22,40–42], and selecting and maintaining the
optimal starting dose is crucial to the successful manage-
ment of chronic HCV.trials of peginterferon alfa plus ribavirin. (a) SVR rates following 48
weeks of peginterferon alfa-2a plus 800 mg/day ribavirin [12] and 48
weeks of peginterferon alfa-2a plus 800 mg/day or standard dose
ribavirin at 1000/1200 mg/day [13]. (b) SVR rates following 48 weeks
of peginterferon alfa-2b plus 800 mg/day ribavirin [11] and 48 weeks of
peginterferon alfa-2b plus ribavirin at 800 mg/day or weight-based dosing
at 800–1400 mg/day [43].4. Clinical considerations in ribavirin dosing
There are several important considerations that a
physician must make when prescribing ribavirin, includ-
ing selecting the appropriate starting dose, maintaining
this dose by careful clinical management of any ribavi-
rin-related side eﬀects by incrementally decreasing the
ribavirin dose, and determining when to return to the
indicated dose following successful side eﬀect manage-
ment. It is also crucial to continue ribavirin to the end
of therapy where possible, as even late discontinuation
can have a strong negative impact on clinical outcomes.
4.1. Selecting the appropriate starting dose
A relationship between ribavirin dose and response to
therapy with both interferon alfa-2a and 2b has been
established in genotype 1 patients, who beneﬁt from
doses >800 mg/day [11–13,43]. When ribavirin is com-
bined with peginterferon alfa-2a, relatively small reduc-
tions to 800 mg/day lead to signiﬁcantly lower rates of
SVR (odds ratio [OR] standard versus low dose: 1.55,
95% conﬁdence interval [CI]: 1.14, 2.10; p = 0.005;
Fig. 2a) [13]. Similarly, a large, comparative trial of
ﬁxed-dose ribavirin compared with weight-based dosing
in combination with peginterferon alfa-2b, showed thatstratifying patients of all genotypes to receive starting
doses ranging from 800–1400 mg/day dependent on
weight leads to a signiﬁcantly higher SVR rate than
using a ﬁxed dose of 800 mg/day for all patients
(44.2% versus 40.5%, respectively; p = 0.008; Fig. 2b)
[43]. Of note, this eﬀect was most profound in patients
with genotype 1 disease (34.0% versus 28.9%, respec-
tively; p = 0.005) [43].
A detailed analysis of the relationship between body-
weight and SVR suggests that the dose per kilogram
may be the determining factor of response in genotype
1 patients (Fig. 3a), with a 40–50% increase in probabil-
ity of SVR for a 12–16 mg/kg dose ribavirin increase
[40]. Ribavirin dosage by weight may impact plasma
concentration of the drug, which has also been shown
to correlate with response [41]. While this relationship
has been well documented in genotype 1 patients, data
are less clear for other genotypes. A plasma concentra-
tion–response relationship has been suggested for non-
genotype 1 patients [41], but another study showed no
Fig. 3. The relationship between ribavirin dose and probability of an
SVR in patients with chronic HCV treated with peginterferon alfa-2a
plus ribavirin. (a) In genotype 1 patients. (b) In genotype 2/3 patients
[40].
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genotype 2/3 patients (Fig. 3b) [40].
Based on these data, weight-based dosing has been
utilized more extensively in patients with genotype 1
HCV, and is required in order to achieve maximum eﬃ-
cacy. The standard initial ribavirin dose in patients with
HCV genotype 1 is 1000/1200 mg/day (1000 mg/day
675 kg; 1200 mg/day >75 kg) over a 48-week treatment
course, although higher ribavirin doses are considered
for patients >85 kg. A large population pharmacoki-
netic analysis involving 380 patients has shown that
the pharmacokinetics of ribavirin are highly variable,
with lean body weight emerging as the only factor that
inﬂuences clearance, supporting the use of these two dis-
tinct weight-based doses in patients with genotype 1 dis-
ease [44]. However, caution must be exercised with
weight-based dosing above 1200–1400 mg. Although
data modeling from patients who received this standard
starting dose suggests that SVR increases linearly with
ribavirin doses that equate to >10 mg/kg, there is also
a simultaneous linear increase in the rate of anemia
(<10 g/dL hemoglobin) [40]. A ribavirin dose of
15 mg/kg/day might achieve the best balance between
eﬃcacy and a manageable safety proﬁle.In some patient groups, such as genotype 2/3 patients
or those with a very high sensitivity to peginterferon
alfa, ribavirin dose reductions are being assessed.
Interim analysis of a randomized study of peginterferon
alfa plus ribavirin for 24 weeks at doses of either 400 or
800 mg suggests no decrease in SVR rates in the lower-
dose group [45]. Lower doses of ribavirin may also be
appropriate in certain patient groups who could not
otherwise tolerate ribavirin therapy, such as those with
renal impairment. With careful monitoring of plasma
concentrations to avoid over dosing, ribavirin doses of
200–800 mg/day have been successfully administered in
a small cohort of renally impaired patients [46].
Although ﬁve of these seven patients required treatment
for ribavirin-induced hemolytic anemia, virologic and
renal remission were achieved and maintained in four
patients [46]. Similarly, patients in dialysis with end-
stage renal disease may also beneﬁt from peginterferon
alfa plus ribavirin, with SVRs described in three of six
patients who received carefully monitored ribavirin
doses of 170–300 mg/day [47]. Although ribavirin is
not recommended for use in patients with renal impair-
ment [48,49], these reports suggest that reduced ribavirin
at 200–400 mg/day can be safely dosed and may allow
for more successful treatment [46,47,50].
4.2. Achieving the optimal duration of ribavirin therapy
The duration of combined therapy with peginterferon
alfa plus ribavirin has a signiﬁcant impact on therapeu-
tic outcomes, and it is important to continue both ther-
apies for the full treatment course to obtain the best
response. The optimal duration of combined therapy is
genotype speciﬁc; in genotype 1 patients, reducing the
duration of treatment from the recommended 48 to 24
weeks results in a >10% reduction in SVR (OR 24 versus
48 weeks: 2.19; 95% CI: 1.52, 3.16; p < 0.0001) [13].
However, shorter treatment courses may be viable in
select genotype 1 patient populations such as those
who achieve a rapid virologic response and have a low
pre-treatment HCV viral load [51,52]. In genotype 2/3
patients, a 24-week duration of treatment with a ﬁxed
800 mg/day dose of ribavirin is suﬃcient to achieve an
optimal response in the majority of patients [13]. As well
as considering the total duration of treatment, it is also
important to maintain the ribavirin component of ther-
apy throughout the entire treatment course. Genotype 1
patients who discontinue ribavirin after 24 weeks while
continuing on peginterferon alfa show signiﬁcantly
higher rates of breakthrough and relapse than those
who continue on combined therapy for the full 48 weeks
(SVR 52.8% versus 68.2%, respectively; p = 0.004) [19].
However, patients with an early response within 2 weeks
of initiating therapy may not require the full 48 weeks of
ribavirin to sustain this response [19]. This is supported
by further evidence from the DITTO trial of dynamically
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the length of treatment in patients who achieve an early
response may still allow for optimal virologic control. In
this study, reducing the length of therapy from 48 to 24
weeks in rapid responders allowed for equivalent viro-
logic eﬃcacy, although no improvements in response
were seen [53]. Similarly, assigning a 12- or 24-week
course, depending on rapid viral response (RVR), to
patients receiving peginterferon alfa-2b plus ribavirin
is as eﬀective as using a 24-week course for all patients
[16].
4.3. The impact of cumulative ribavirin exposure on
response to therapy
As data emerge to suggest that both the starting dose
of ribavirin and duration of treatment aﬀect response to
therapy, it now seems increasingly likely that total
cumulative exposure is critical to achieve an optimal
SVR for all patient groups. In patients with genotype
1 HCV, as cumulative ribavirin exposure decreases,
there is a concomitant decrease in SVR and increase in
rates of relapse [14,19]. The eﬀect on SVR is indepen-
dent of peginterferon alfa exposure, as patients who
receivedP97% of their intended peginterferon alfa dose
but <60% of the target cumulative ribavirin dose had
dramatically lower SVR rates than those who received
P60% of the planned ribavirin dose (33% versus 64%,
respectively; p < 0.0001; Fig. 4) [14]. The eﬀect of cumu-
lative ribavirin dose on response to therapy appears to
be consistent whether the reduced exposure is mainly
due to prolonged periods of drastic (>200 mg) dose
reduction, temporary interruptions and/or premature
cessation of ribavirin therapy [14]. Furthermore, reduc-
tions in SVR have also been described in patients who
received >97% of the planned ribavirin dose during
weeks 1–12 but reduced exposure during weeks 13–48,
demonstrating that maintaining ribavirin exposure over
the whole duration of therapy is crucial, not just up to
week 12 [14]. Therefore, maintaining the patient on theFig. 4. The impact of ribavirin dose reductions on relapse rates in
patients with genotype 1 chronic HCV treated with peginterferon alfa-2a
plus ribavirin [14].starting dose for as long as possible, reducing it in small
decrements in patients who do not tolerate their starting
dose, and stepping back up to the starting dose once
toxicities have been resolved are key to maximizing the
chance of a successful response. The clinical importance
of maintaining ribavirin exposure has also been con-
ﬁrmed in a real-world setting, using data from a large
peginterferon alfa-2a expanded access program [42].
Current treatment guidelines recommend discontinu-
ation of therapy in patients who experience severe
adverse events, such as hemoglobin levels <8.5 g/dL.
For more moderate toxicities such as hemoglobin 8.5–
10 g/dL, the labeling varies depending on whether
peginterferon alfa-2a or -2b is being administered. In
combination with peginterferon alfa-2a, both the US
and EU labels recommend decreasing the ribavirin dose
to 600 mg/day to combat moderate toxicities [54,55].
The advice is the same in the US for ribavirin when
taken in combination with peginterferon alfa-2b [56].
However, the EU label is more complex, and indicates
ribavirin dose reduction for some moderate adverse
events such as hemoglobin <10 g/dL, but reduction of
peginterferon alfa-2b dose only for the management of
other adverse events such as low white blood cell, neu-
trophil or platelet counts [57]. Despite these recommen-
dations, as described above, the majority of clinical data
suggest that 200 mg stepwise decrements might be pref-
erable to maintain exposure during treatment. This
approach allows reduction in the dose per kg of body-
weight to approximately 80% of the starting dose across
a broad weight range, whereas immediate reduction to
600 mg/day results in an eﬀective 50–60% reduction in
the ribavirin dose per kg (Table 1), therefore incremental
dose reductions may help avoid the reduced SVRs
described with cumulative exposure to <60% of the
planned ribavirin dose [14]. Early and proactive man-
agement of adverse events may help reduce the need
for further dose reductions and render this a viable
approach to patient management; for example, epoetin
therapy may be a suitable approach in some patients
with moderately reduced hemoglobin levels, a strategy
that will be discussed in detail in the next section.
In patients with diﬃcult-to-cure characteristics, such
as weight >85 kg or high viral load, higher ribavirin
starting doses (>1200 mg/day) may help increase
response rates. For example, patients with genotype 1
HCV, high viral load and weighing >85 kg have an
increased SVR with 1600 mg/day ribavirin plus pegin-
terferon alfa compared with the standard of care [58].
Body weight has a large impact on ribavirin clearance
[41], and higher ribavirin doses may help ensure that a
high enough serum concentration, and therefore suﬃ-
cient cumulative exposure to ribavirin, is achieved and
maintained in this patient population. Indeed, one small
study has demonstrated that administering ribavirin at
up to twofold higher than the recommended dose (mean
Table 1
Eﬀect of ribavirin (RBV) starting doses and diﬀerent RBV dose reduction strategies on administered dose and percentage dose reduction.
Patient weight (kg) Ribavirin dosing according to peginterferon alfa-2a prescribing
information [54,55]
Ribavirin dosing according to peginterferon alfa-
2b prescribing information [56,57]
RBV dose
at start
of therapya
RBV dose
following
ﬁrst dose
reduction
mg/daya
Dose reduction from
starting dose to
after ﬁrst dose reduction (%)
RBV dose
at start
of therapya
RBV dose
following ﬁrst
dose reductiona
Dose reduction
from starting dose
to after ﬁrst dose
reduction (%)aBased on prescribing
informationa
Based on ﬁxed
200 mg dose reduction
50 1000 600 60 80 800 600 75
60 1000 600 60 80 800 600 75
70 1000 600 60 80 1000 800 80
80 1200 600 50 83 1000 800 80
90 1200 600 50 83 1200 1000 83
100 1200 600 50 83 1200 1000 83
110 1200 600 50 83 1400 1200 86
120 1200 600 50 83 1400 1200 86
a Starting dose and dose reductions according to current prescribing information.
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10 genotype 1 patients [59]. However, careful patient
management is required with high ribavirin dosing to
minimize potential dose-related toxicities [58,59]. A
large clinical trial is currently underway to determine
whether induction doses (360 lg/week for the ﬁrst 12
weeks of therapy) of peginterferon alfa and/or increased
ribavirin (up to 1600 mg/day according to bodyweight)
will increase response rates in diﬃcult-to-cure patients
with genotype 1 HCV.5. Management of ribavirin-associated anemia
Successful management of ribavirin-associated toxic-
ity is necessary to maintain the optimal ribavirin dose in
all patients, and a particular emphasis be made on the
diagnosis and management of hemolytic anemia, which
is the most common reason for ribavirin dose reduction
or treatment discontinuation [12,13,60]. The mechanism
driving ribavirin-induced anemia is complex [61,62],
however it has been observed that the concentration of
ribavirin is up to 60-fold higher in erythrocytes than in
blood serum [63].
Close monitoring of patients with increased risk fac-
tors for anemia is important, as early interventions such
as modest reductions of ribavirin or prophylactic ther-
apy could prevent a later more drastic reduction when
a signiﬁcant anemia has developed. Indeed, an early
drop in hemoglobin of P1.5 g/dL after just 2 weeks of
therapy is predictive of a larger drop by P2.5 g/dL by
week 4 [64,65]. Other risk factors that may warrant clo-
ser monitoring for anemia include age (increased risk
with every 10-year increase), low baseline hemoglobin
(increased risk with every 1 g/dL decrease) and low cre-
atinine clearance (increased risk with every 10 mL/min
decrease) [65]. Although many clinical trials have used
large dose reductions (600 mg) to manage side eﬀects,consideration should be given to smaller dose reductions
of 200 mg at a time, to help ensure that maximum riba-
virin exposure is maintained and antiviral eﬃcacy is not
compromised.
Ribavirin dose reductions can help stabilize falling
hemoglobin levels, but only tend to lead to modest
improvements of1 g/dL [60]. Although the approaches
taken to manage anemia vary widely, in some cases oﬀ-
label use of epoetin alfa therapy may be considered to
counteract anemia and help maintain the optimal ribavi-
rin dose. Although this treatment option is expensive and
not an approved form of therapy, the impact on hemo-
globin levels is stronger than that of ribavirin dose reduc-
tion, with a mean change of +2.8 g/dL reported after 16
weeks of therapy, compared with +0.4 g/dL with the
standard of care (p < 0.0001) [66]. This translates into a
clinically important diﬀerence in the number of patients
maintaining the desired ribavirin dose, which in this case
was deﬁned as P800 mg/day (83% versus 54%, respec-
tively; p = 0.022) [66]. This ﬁnding was mirrored by a
second study, in which patients with anemia during ther-
apy with peginterferon alfa plus ribavirin were random-
ized to epoetin therapy or placebo and signiﬁcantly more
maintained their ribavirin dose in the epoetin group
(88% versus 60%; p < 0.001) [67]. Epoetin is also gener-
ally well tolerated in this clinical context, and an
improvement in quality of life accompanies these raised
hemoglobin levels [67]. Despite these positive ﬁndings,
a recent study has suggested that although epoetin use
reduces the need for ribavirin dose reductions, this does
not translate into an improvement in SVR [68]. How-
ever, it is worth noting that this study included a group
of patients treated with a higher dose of ribavirin
(15.2 mg/kg/day) plus epoetin, 93% of whom achieved
P80% maximal cumulative ribavirin dose. Signiﬁcantly
higher rates of SVR were seen in this patient group than
those randomized to a standard dose of ribavirin
(13.3 mg/kg/day), with or without epoetin (49% with
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ribavirin + epoetin versus 19% with lower dose ribavirin
alone; p < 0.05) [68]. Lastly, the potential beneﬁt of epoe-
tin must be balanced against the risks. Reports have
emerged highlighting increased mortality and serious
cardiovascular and thromboembolic events in patients
who received erythropoiesis-stimulating agents to target
higher hemoglobin levels, particularly in patients with
renal failure and perisurgical patients [61]. In order to
minimize this risk, the recommended target hemoglobin
level is in the range of 10–12 g/dL [69]. Given these con-
cerns, our own practice has been to consider oﬀ-label
epoetin use in order to prevent ribavirin discontinuation
and pay careful attention to maintaining hemoglobin lev-
els <12 g/dL with epoetin therapy.
While the precise role of epoetin has yet to be deﬁned,
it is clear that careful patient management is warranted
to monitor and pro-actively address ribavirin-associated
hemolytic anemia, and the development of guidelines to
help direct treatment strategies for the use of epoetin
alongside ribavirin combination therapy is warranted.
In cases of severe anemia, treatment discontinuation
and transfusion may be considered as alternative thera-
peutic options, but with careful clinical management this
scenario should rarely arise [61]. Given the relationship
between anemia, ribavirin dose and SVR, one future
consideration may be whether anemia itself could be
regarded as a positive predictive factor for response to
ribavirin combination therapy.6. Alternatives to ribavirin
6.1. Ribavirin-like drugs
Peginterferon alfa plus ribavirin is currently the stan-
dard of care for patients with chronic HCV infection of
all genotypes, however novel therapies that may be suit-
able for addition to this treatment paradigm or as
replacements for ribavirin are constantly under develop-
ment. In particular, there is a need for novel therapies
with comparable eﬃcacy to ribavirin, but improved tol-
erability. One such candidate, taribavirin, is an oral pro-
drug of ribavirin that is deaminated to ribavirin in the
liver, and therefore accumulates less than standard riba-
virin in red blood cells and may be associated with lower
rates of anemia. It is being developed as an alternative to
standard ribavirin with the objective of reducing ribavi-
rin-related hemolytic anemia.
Two Phase III trials of taribavirin versus ribavirin in
combination with peginterferon alfa-2a have been per-
formed to date, VISER 1 and 2. Both have indicated
that while anemia rates are signiﬁcantly lower among
patients receiving taribavirin, rates of SVR are also
lower (38% with taribavirin versus 52% with ribavirin
across all genotypes with VISER 1, 40% versus 55%,respectively, in VISER 2) [70,71]. These results were dis-
appointing and suggested that the dosing regimen of
taribavirin will need to be increased to improve SVR,
but this may also increase the anemia advantage seen
at lower dosing. Speciﬁc inosine-monophosphate-dehy-
drogenase (IMPDH) inhibitors have also been devel-
oped and may show promise as alternative to
ribavirin, such as merimepodib, mycophenolate mofetil
and VX-497. Of these alternative agents, merimepodib
has been studied for the treatment of HCV in most
detail, and a Phase II trial in combination with peginter-
feron alfa and ribavirin showed undetectable HCV
RNA at 24 weeks in 100% of patients on the higher
50 mg dose, compared with only 33% of patients who
received peginterferon plus ribavirin alone [72].
6.2. The role of ribavirin in future STAT-C therapies
A number of speciﬁcally targeted antiviral therapies
for HCV (STAT-Cs) are under development, with multi-
ple protease and polymerase inhibitors entering into
Phase I and II testing. Over the past year, we have
learned a great deal about the role of ribavirin in these
small molecule combination regimens. For example,
the HCV protease inhibitors telaprevir (VX-950) and
bocepravir are currently under investigation. Telepravir
is being studied in combination with peginterferon alfa
alone or with ribavirin in patients with genotype 1 dis-
ease, and preliminary data from Phase II trials suggest
that adding telepravir leads to earlier viral responses in
a higher proportion of patients [73,74]. In a Phase II
study which included an arm where patients received
only peginterferon alfa and telaprevir without ribavirin
there was a dramatic impact on relapse rates and
SVR, indicating that ribavirin will likely remain an
essential part of newly emerging treatments [73].
Another promising group of novel therapeutics are
the HCV polymerase inhibitors, which may be suitable
candidates for addition to the current treatment regi-
men. The nucleoside analog R1626 is a pro-drug of
the R1479 NS5B polymerase inhibitor, which is known
to inhibit viral RNA replication via chain termination
[75], a mechanism of action that has also been proposed
for ribavirin [31]. A Phase I study of R1626 in combina-
tion with peginterferon alfa-2a and ribavirin has demon-
strated promising antiviral activity compared with
placebo and a favorable tolerability proﬁle [76]. This
study is ongoing to determine the optimal R1626 dose
in chronic HCV, and Phase II trials have also been ini-
tiated to conﬁrm these promising eﬃcacy data and
determine the optimal combination regimen. Impor-
tantly, in vivo synergy has also been observed between
R1626 and peginterferon plus ribavirin or ribavirin
alone, again suggesting that ribavirin will remain an
important initial agent as we add small molecules to
the current standard of care [77].
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The addition of ribavirin to peginterferon alfa
improves SVR rates and decreases the rate of relapse
in patients with HCV infection, an eﬀect that is consis-
tent across genotypes. For this reason, peginterferon
alfa plus ribavirin is the standard of care for the treat-
ment of HCV. Tremendous advances have been made
in our understanding of the role of ribavirin within this
therapeutic regimen: the standard ribavirin dose is cur-
rently thought to be 1000 mg/day for genotype 1
patients <75 kg, 1200 mg/day for genotype 1 patients
P75 kg and 800 mg/day for all genotype 2/3 patients,
although weight-based dosing at 15 mg/kg may yet
prove to be the best approach. The ribavirin dose should
be maintained over a period of 48 weeks for the majority
of patients with genotype 1 disease and for 24 weeks for
the majority of patients with genotype 2/3. Shorter
durations of treatment may be appropriate for selected
patients achieving an RVR with low baseline viral load.
Doses of ribavirin above 1200 mg/day may be consid-
ered in diﬃcult-to-cure patients infected with genotype
1 HCV. Alternatively, the ribavirin dose can be reduced
or even stopped in patients with very high sensitivity to
peginterferon alfa therapy.
Despite these advances in our knowledge, many
questions still remain as to how we can further opti-
mize therapy, for example should ribavirin dose be var-
ied based on pre-treatment HCV viral load, and will
the role of ribavirin alter as new therapies are devel-
oped. Importantly, cumulative ribavirin exposure is a
crucial determinant of response to therapy, therefore
achieving and maintaining the optimal dose through-
out therapy is key to achieving high rates of SVR.
Careful patient management is required to monitor
the toxicities of therapy, in particular hemoglobin lev-
els should be monitored in patients with risk factors
for treatment-induced hemolytic anemia, and dose
reductions or other therapeutic interventions should
be administered in a timely manner. Dose reductions
of ribavirin should be limited to the minimum required
to address side eﬀects, possibly using small decrements
and avoiding reductions to below 60% of the target
dose whenever possible. Consideration should then be
given to stepping the ribavirin dose back up to the tar-
get dose on resolution of adverse events, to maximize
total exposure. At present, there are no alternatives
to ribavirin approved for the treatment of HCV, there-
fore maintaining patients on their indicated dose and
length of therapy is crucial if the goal of a sustained
response is to be achieved.References
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